Plenary session to highlight use of Guardant360 CDx test in detecting emerging ESR1 mutations during first line endocrine therapy in advanced breast cancer in Phase 3 SERENA-6 trial Oral session to ...
At AACR, Guardant Health and a Japanese group showcased data on machine learning models that predict the tissue of origin in cancers of unknown primary.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results